Table 2. Univariate and Multivariate Analysis to Infection risk after orthotopic liver transplantation (N=288).
| Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Bacterial infection % (N) | HR | CI (95%) | P Value | HR | CI (95%) | P Value |
| Age | |||||||
| Recipient | 30.6 (88/288) | 0.99 | 0.98-1.0 | 0.37 | |||
| Donor | 30.6 (88/288) | 0.99 | 0.98-1.0 | 0.11 | |||
| Gender recipiënt | 0.02 | 0.02 | |||||
| Male/male | 40.8 (40/98) | 2.6 | 1.4-5.0 | 0.004 | 2.6 | 1.4-5.0 | 0.004 |
| Male/female | 30.0 (15/50) | 1.8 | 0.84-3.8 | 0.13 | 1.5 | 0.68-3.2 | 0.32 |
| Female/male | 27.6 (21/76) | 1.6 | 0.79-3.3 | 0.19 | 1.5 | 0.71-3.0 | 0.30 |
| Female/female | 18.8 (12/64) | ref | ref | ||||
| Primary liver disease | 0.49 | ||||||
| Viral | 37.5 (21/56) | 1.5 | 0.86-2.6 | ||||
| Alcoholic | 26.3 (10/38) | 1.1 | 0.52-2.1 | ||||
| Cholestatic | 33.3 (25/75) | 1.3 | 0.77-2.2 | ||||
| Other disease§ | 26.9 (32/119) | ref | |||||
| Child-Pugh class | 0.14 | ||||||
| C | 36.8 (35/95) | 1.8 | 0.99-3.4 | 0.05 | |||
| B | 30.0 (39/116) | 1.4 | 0.76-2.6 | 0.29 | |||
| A | 22.2 (14/63) | ref | |||||
| Lab MELD score | 31 (88/288) | 1.0 | 0.97-1.0 | 0.72 | |||
| Donor-type | |||||||
| Donation after cardiac death | 37.5 (9/24) | 1.3 | 0.65-2.6 | 0.47 | |||
| Donation after brain death | 29.9 (79/264) | ref | |||||
| Immunosuppression | |||||||
| Prednisone/CNI/basiliximab (+ MMF) | 28.1 (55/196) | 0.74 | 0.48-1.1 | 0.18 | |||
| Prednisone/CNI (+ azathioprine) | 35.9 (33/92) | ref | |||||
| Acute cellular rejection | |||||||
| Yes | 24.0 (24/100) | 0.60 | 0.38-0.95 | 0.03 | |||
| No | 34.0 (64/188) | ref | |||||
| CMV seropositivity | 0.74 | ||||||
| D+/R+ | 26.4 (23/87) | 0.79 | 0.42-1.50 | 0.47 | |||
| D+/R- | 30.8 (12/39) | 0.95 | 0.45-2.01 | 0.89 | |||
| D-/R+ | 32.5 (37/114) | 1.1 | 0.59-1.90 | 0.85 | |||
| D-/R- | 33.3 (16/48) | ref | |||||
| Lectin complement pathway donor profile‡ | 1.8 | 1.4-2.3 | <0.001 | 1.8 | 1.4-2.3 | <0.001 | |
| 3 variants | 63.2 (12/19) | 4.1 | 1.6-10.4 | 0.003 | 4.1 | 1.6-10.5 | 0.003 |
| 2 variants | 39.8 (41/103) | 2.5 | 1.1-5.5 | 0.03 | 2.3 | 1.0-5.1 | 0.047 |
| 1 variant | 21.7 (28/129) | 1.2 | 0.5-2.6 | 0.73 | 1.1 | 0.47-2.5 | 0.86 |
| 0 variants | 18.9 (7/37) | ref | ref | ||||
| Recipient R702W | 2.1 | 1.1-4.2 | 0.03 | 2.0 | 1.0-4.0 | 0.040 | |
| TT | 100 (1/1) | 18.1 | 2.4-136.6 | 0.005 | |||
| CT | 50.0 (7/14) | 1.7 | 0.80-3.8 | 0.16 | |||
| CC | 29.3 (80/273) | ref |
HR denotes hazard ratio; CI, confidence interval; MELD, Model for End-Stage Liver Disease; CNI, calcineurin inhibitors; MMF, mycophenolate mofetil
‡The presence of donor-recipient genotypic groups associated with bacterial infections within the individual were clustered as lectin pathway donor profile; MBL2: XA/O and O/O donor and A/A and YA/O recipient; FCN2: CT or TT donor and or recipient; MASP2: AA donor and or recipient